Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.

Authors :: Furst DE
Keystone EC
Kirkham B
Kavanaugh A
Fleischmann R
Mease P
Breedveld FC
Smolen JS
Kalden JR
Burmester GR
Braun J
Emery P
Winthrop K
Bresnihan B
De Benedetti F
Dörner T
Gibofsky A
Schiff MH
Sieper J
Singer N
Van Riel PL
Weinblatt ME
Weisman MH
Source :: Annals of the rheumatic diseases [Ann Rheum Dis] 2008 Dec; Vol. 67 Suppl 3, pp. iii2-25.
Publication Year :: 2008

Subjects :: Abatacept
Antibodies, Monoclonal adverse effects
Antibodies, Monoclonal therapeutic use
Antibodies, Monoclonal, Murine-Derived
Antirheumatic Agents adverse effects
Arthritis drug therapy
Evidence-Based Medicine
Humans
Immunoconjugates adverse effects
Immunoconjugates therapeutic use
Immunologic Factors adverse effects
Interleukin-1 antagonists & inhibitors
Interleukin-2 antagonists & inhibitors
Opportunistic Infections chemically induced
Rituximab
Tumor Necrosis Factor-alpha antagonists & inhibitors
Antirheumatic Agents therapeutic use
Immunologic Factors therapeutic use
Rheumatic Diseases drug therapy

Full Text Access

Tools